Las Vegas Clinical Trials
Welcome,         Profile    Billing    Logout  
 1 Trial 
16 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dunn, Michael
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

Active, not recruiting
4
156
US
APRETUDE, Cabotegravir tablet
ViiV Healthcare
HIV Infections
08/25
08/25
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Active, not recruiting
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
FrAILT, NCT03228290: Functional Assessment in Liver Transplantation

Recruiting
N/A
5000
US
University of California, San Francisco, National Institute on Aging (NIA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Liver Disease
12/28
12/28
ECALC, NCT05616247: Efficacy of the Expectancy Challenge Alcohol Literacy Curriculum on Reducing College Student Alcohol Use and Harms

Enrolling by invitation
N/A
360
US
ECALC, ECALC Plus Weekly Boosters
University of Central Florida
Alcohol Use, Underage, Harmful; Use, Alcohol
05/25
09/25
Person, Central Contact
ENIGMA-SC, NCT05152563: A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Withdrawn
3
280
US
AK002, Lirentelimab, Placebo
Allakos Inc.
Eosinophilic Gastritis, Eosinophilic Duodenitis
01/22
01/22
ATLAS, NCT05155085 / 2022-001625-79: A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Terminated
2
131
Europe, US
AK002, Lirentelimab, Placebo
Allakos Inc., Allakos Inc.
Atopic Dermatitis
12/23
04/24
MAVERICK, NCT05528861 / 2022-001847-26: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Terminated
2
127
Europe, US
Lirentelimab (AK002), AK002, Placebo
Allakos Inc., Allakos Inc.
Chronic Spontaneous Urticaria
12/23
04/24
Walters, Alton
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Terminated
2
113
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
12/24
01/25
NCT06865079: 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Recruiting
2
270
US
TPX-100 200mg, Once weekly for 4 weeks, PBS
OrthoTrophix, Inc
Osteoarthritis (OA) of the Knee
05/27
06/27
Abdelsayed, Nader
MERMAID, NCT06121063: CCT-102 or Expectant Management in Delayed Pregnancy Loss

Active, not recruiting
3
183
US
CCT-102 A and CCT-102 B
Conceptra Biosciences, LLC
Early Pregnancy Loss, Delayed Pregnancy Loss
05/25
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dunn, Michael
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

Active, not recruiting
4
156
US
APRETUDE, Cabotegravir tablet
ViiV Healthcare
HIV Infections
08/25
08/25
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Active, not recruiting
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
FrAILT, NCT03228290: Functional Assessment in Liver Transplantation

Recruiting
N/A
5000
US
University of California, San Francisco, National Institute on Aging (NIA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Liver Disease
12/28
12/28
ECALC, NCT05616247: Efficacy of the Expectancy Challenge Alcohol Literacy Curriculum on Reducing College Student Alcohol Use and Harms

Enrolling by invitation
N/A
360
US
ECALC, ECALC Plus Weekly Boosters
University of Central Florida
Alcohol Use, Underage, Harmful; Use, Alcohol
05/25
09/25
Person, Central Contact
ENIGMA-SC, NCT05152563: A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Withdrawn
3
280
US
AK002, Lirentelimab, Placebo
Allakos Inc.
Eosinophilic Gastritis, Eosinophilic Duodenitis
01/22
01/22
ATLAS, NCT05155085 / 2022-001625-79: A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Terminated
2
131
Europe, US
AK002, Lirentelimab, Placebo
Allakos Inc., Allakos Inc.
Atopic Dermatitis
12/23
04/24
MAVERICK, NCT05528861 / 2022-001847-26: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Terminated
2
127
Europe, US
Lirentelimab (AK002), AK002, Placebo
Allakos Inc., Allakos Inc.
Chronic Spontaneous Urticaria
12/23
04/24
Walters, Alton
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Completed
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
01/25
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Terminated
2
113
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
12/24
01/25
NCT06865079: 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Recruiting
2
270
US
TPX-100 200mg, Once weekly for 4 weeks, PBS
OrthoTrophix, Inc
Osteoarthritis (OA) of the Knee
05/27
06/27
Abdelsayed, Nader
MERMAID, NCT06121063: CCT-102 or Expectant Management in Delayed Pregnancy Loss

Active, not recruiting
3
183
US
CCT-102 A and CCT-102 B
Conceptra Biosciences, LLC
Early Pregnancy Loss, Delayed Pregnancy Loss
05/25
05/25

Download Options